Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

Rights & Permissions Free Resources Display this book on your site! Related Titles Naval Forces' Defense Capabilities Against Chemical and Biological Warfare Threats Protecting Our Forces:Improving Vaccine Acquisition and Availability in the U.S. Military Other Related Titles Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report (2003) Medical Follow-Up Agency (MFUA) Institute of Medicine (IOM) Board on Life Sciences (BLS) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix: Agendas for Information-Gathering Meetings." Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report. Washington, DC: The National Academies Press, 2003. Please select a format: Page 5   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix Agendas for Information-Gathering Meetings Meeting I December 16–17, 2002 The National Academy of Sciences Building 2101 Constitution Avenue, NW Washington, DC   Monday, December 16, 2002 1:15 p.m. Introductory Remarks Leslie Benet, Ph.D., Chair, Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents   Introductions by Committee Members and Meeting Attendees 1:30 Sponsor Presentation on the Study Charge Carol Linden, Ph.D., Director, Medical Chemical and Biological Defense Research Program, U.S. Army Medical Research and Materiel Command   Congressional Comment on the Study Charge Mr. Jean Reed, Professional Staff Member, House Armed Services Committee   Discussion 2:30 Status of Department of Defense Effort on Accelerating Research, Development, and Acquisition of Medical Countermeasures Anna Johnson-Winegar, Ph.D., Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense   Discussion 3:15 Break Page 5 Front Matter (R1-R10) Interim Report (1-4) Appendix: Agendas for Information-Gathering Meetings (5-8)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 5
Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report Appendix Agendas for Information-Gathering Meetings Meeting I December 16–17, 2002 The National Academy of Sciences Building 2101 Constitution Avenue, NW Washington, DC   Monday, December 16, 2002 1:15 p.m. Introductory Remarks Leslie Benet, Ph.D., Chair, Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents   Introductions by Committee Members and Meeting Attendees 1:30 Sponsor Presentation on the Study Charge Carol Linden, Ph.D., Director, Medical Chemical and Biological Defense Research Program, U.S. Army Medical Research and Materiel Command   Congressional Comment on the Study Charge Mr. Jean Reed, Professional Staff Member, House Armed Services Committee   Discussion 2:30 Status of Department of Defense Effort on Accelerating Research, Development, and Acquisition of Medical Countermeasures Anna Johnson-Winegar, Ph.D., Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense   Discussion 3:15 Break

OCR for page 6
Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report 3:30 CBER Perspective on Opportunities for Accelerating Licensure of Medical Counter-measures for Biowarfare Agents Kathryn Zoon, Ph.D., Director, Center for Biologics Evaluation and Research, Food and Drug Administration   Discussion 4:15 CDER Perspective on Opportunities for Accelerating Licensure of Medical Countermeasures for Biowarfare Agents Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration   Discussion 5:00 Adjourn   Tuesday, December 17, 2002 8:00 a.m. Breakfast 8:30 Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military IOM Report, September 2002 Stanley Lemon, M.D., Chair, IOM Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military   Discussion 9:15 DoD Acquisition of Vaccine Production Report to the Deputy Secretary of Defense, December 2000 Gerald V.Quinnan, Jr., M.D., Professor and Chair of Preventive Medicine, Uniformed Services University of the Health Sciences   Discussion 10:00 Adjourn

OCR for page 7
Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report Meeting II January 14–15, 2003 The National Academies Building 500 Fifth Street, NW Washington, DC   Tuesday, January 14, 2003 9:00 a.m. Breakfast 9:30 Introductory Remarks Leslie Benet, Ph.D., Chair, Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents 9:45 Medical Countermeasures for Biological Warfare Agents Research Carried out at/through the U.S. Army Medical Research and Materiel Command (USAMRMC) Carol Linden, Ph.D., Director, Medical Chemical and Biological Defense Research Program, USAMRMC 10:30 Break 10:45 Chemical and Biological Medical Systems (CBMS) (formerly Joint Vaccine Acquisition Program) COL David Danley, Ph.D., Director, CBMS 11:30 DynPort Vaccine Company LLC Michael J.Langford, Ph.D., Senior Vice President and Chief Scientific Officer, DynPort Vaccine Company LLC 12:00 p.m. Working Lunch 12:45 Defense Threat Reduction Agency (DTRA) LTC Keith R.Vesely, D.V.M., Ph.D., Chief, Medical Science and Technology Division, Chemical and Biological Defense Directorate 1:15 Defense Advanced Research Projects Agency (DARPA) John Carney, Ph.D., Unconventional Pathogen Countermeasures Program 1:45 Joint Program Executive Office for the Chemical and Biological Defense Program (JPEO-CBDP) BG Steve Reeves, Program Executive Officer, Chemical and Biological Defense

OCR for page 8
Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report 2:15 Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear (JRO-CBRN) Defense MAJ Ronald Fizer, Joint Requirements Integrator, JRO-CBRN Defense 2:45 Break 3:00 Directed Roundtable Discussion: Representatives of Involved Government and Other Organizations   For each category, a set of questions was circulated to direct to the group   3:00 I Basic Research Early Development   3:45 II Transition to Advanced Development   4:30 III Advanced Development Licensure 5:30 Summary and General Discussion 6:00 Adjourn

Representative terms from entire chapter:

medical countermeasures